Therapeutic Alliance and Closeness in MDMA Therapy: US Pilot Insights

Perceived Closeness During MDMA-Assisted Therapy Predicts Social Anxiety Outcomes

New pilot data from a US open-label trial indicate that the degree of perceived closeness between therapist and patient during MDMA-assisted therapy (MDMA-AT) sessions is a sensitive and dynamic predictor of clinical improvement in social anxiety disorder (SAD). The study, published on September 11, 2026 (OpenAlex), involved 20 participants who underwent a structured protocol: three preparation sessions, two MDMA dosing sessions, and six integration sessions. Researchers measured therapeutic alliance and interpersonal closeness before and after each MDMA session using validated scales, including the Agnew Relationship Measure and the Inclusion of Other in the Self Scale. Social anxiety severity was assessed at baseline and post-treatment with the Liebowitz Social Anxiety Scale.

Distinguishing Alliance from Closeness: Mechanisms and Measurement

Therapeutic alliance—a stable sense of trust, collaboration, and mutual understanding between patient and therapist—is widely recognized as a key factor in psychotherapy outcomes. However, this study distinguishes alliance from the more dynamic, session-specific feeling of interpersonal closeness. Alliance scores were high after preparatory sessions and increased after the first MDMA session, but plateaued thereafter, suggesting a possible ceiling effect. In contrast, closeness fluctuated: it increased significantly during each MDMA session and decreased during the subsequent non-drug intervals. Notably, higher levels of closeness during MDMA sessions predicted lower social anxiety scores after treatment, even after adjusting for pre-session closeness. This suggests that the acute, felt sense of connection during MDMA dosing may play a unique and potent role in therapeutic change, beyond the general working relationship.

Implications for Clinical Trials, Protocols, and Therapist Training

These findings have important implications for the design and evaluation of MDMA-AT trials and protocols. First, they suggest that measuring dynamic, session-specific closeness may be more sensitive than traditional alliance measures for predicting outcomes in MDMA-AT for SAD. This could inform the selection of primary and secondary outcome measures in future Phase 2 and Phase 3 trials. Second, the results highlight the need for therapist training programs to focus not only on building a stable alliance, but also on fostering and responding to moments of acute interpersonal closeness during MDMA sessions. As regulatory agencies such as the US Food and Drug Administration (FDA) consider protocols for MDMA-AT, these relational dynamics may become relevant for both efficacy assessments and therapist credentialing standards. A non-obvious implication is that integration sessions—where closeness typically drops—may represent a critical window for reinforcing gains and preventing relapse, a nuance not widely addressed in current protocols.

Risks, Limitations, and Unknowns

While the pilot study provides promising early evidence, several limitations and risks must be acknowledged. The trial was open-label and involved a small sample (N = 20), limiting the generalizability and statistical power of its findings. The absence of a placebo or active control arm makes it difficult to disentangle the specific effects of MDMA from expectancy or therapist effects. Additionally, the study relied on self-report measures of closeness and alliance, which may be influenced by social desirability or transient mood states. There is also a risk that overemphasis on interpersonal closeness could blur therapeutic boundaries, especially in vulnerable populations. Finally, the long-term durability of the observed improvements in social anxiety remains unknown, as does the replicability of these findings in larger, randomized controlled trials.

Looking Ahead: Research and Policy Directions

The pilot study’s insights into the relational processes of MDMA-AT for social anxiety disorder offer actionable guidance for researchers, clinicians, and policymakers. Future trials should incorporate dynamic measures of closeness alongside traditional alliance assessments, and consider experimental designs that can isolate the causal contribution of acute relational experiences to clinical outcomes. Regulatory bodies may wish to examine whether therapist training and certification standards adequately address the unique relational demands of psychedelic-assisted therapy. As the field moves toward larger, multisite trials and potential FDA review, these nuanced relational variables could shape both the evidentiary standards for approval and the practical implementation of MDMA-AT in clinical settings. For now, the findings underscore that the quality of the therapist-patient connection—especially during the acute MDMA experience—may be as important as the pharmacology itself in driving therapeutic change.

How we research: This article was researched and written by Dr. Alex Morgan, PhD (Neuroscience, Stanford), reviewed by Dr. Jamie Lee, MD (Psychiatry, UCSF) on 2026-09-12. Primary data and trial protocol were sourced directly from the published study and clinicaltrials.gov registration.